About Iovance Biotherapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.iovance.com/
Frequently Asked Questions
What is the 52-week range for IOVA?
The 52-week high is $15.3 and the 52-week low is $1.76.
What is the P/E ratio for IOVA?
The P/E ratio data is currently unavailable.
What is the dividend yield for IOVA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -40.51%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -89.09%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.55.
Analyst Recommendation Trends
Wall Street analyst consensus for IOVA over the last few months:
Latest IOVA News
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026. “We are pleased to welcome Noah to Iovance as we pre
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.
Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18
Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $14 to $18.
Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?
Shares of Iovance Biotherapeutics are trading slightly lower Wednesday morning, taking a breather after Tuesday's surge which pushed the stock to a new 52-week high.
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
The rallies were driven by expanding opportunities tied to biotechnology and artificial intelligence.
Iovance Biotherapeutics (IOVA) Eyes 60% Revenue Growth, Shares Jump 31%
Iovance Biotherapeutics (NASDAQ:IOVA) saw its share price increase by 31.48 percent on Tuesday to finish at $14.45 apiece after raising its full-year revenue growth guidance by as much as 60 percent, thanks to the strong demand for its cancer treatments. In an updated report on the same day, the company said that it is now […]
Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why These 5 Stocks Are on Investors' Radars Today
FICO, IOVA, SDEV, CCL, MU were among the trending stocks on Tuesday, Sept. 29, 2026.
Apple, Meta, Iovance, Carnival, Fair Isaac, Bloom Energy, SpaceX, and More Stocks That Explain Today’s Market
Nvidia fell 0.3%, reversing from Monday’s gains when it announced a $150 billion expansion to its stock buyback plan and software to tackle the problem of AI safety. Navitas Semiconductor rose 1.1% after it received a U.S. Army grant to develop power semiconductor technology.
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session.
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Most active stocks in Tuesday's session
Curious about the most active stocks on Tuesday? Find out which stocks are dominating the market action!
These stocks are moving in today's session
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Iovance: The Turnaround Is Priced In, Downgrading To Hold
Iovance Biotherapeutics, Inc. stock surges as AMTAGVI launch beats expectations; FY26 guidance raised. Click here to read this IOVA update.
Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth
Shares of Iovance Biotherapeutics surged Tuesday after the biotech company raised its fiscal-year revenue guidance, thanks to rising demand for a pair of melanoma treatments. Iovance stock rose 28% to $14.06, pacing toward its highest close since May 7, 2024, when shares reached $13.98, according to Dow Jones Market Data. Iovance raised its fiscal 2026 revenue guidance to between $410 million and $420 million, driven by strong U.S. demand for Amtagvi and Proleukin, the company said.
Traders are paying attention to the gapping stocks in Tuesday's session.
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook
Iovance raised its 2026 revenue forecast due to strong U.S. demand for Amtagvi and Proleukin cancer therapies.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Iovance Raises 2026 Revenue Guidance to $410 Million-$420 Million
Iovance Biotherapeutics (NASDAQ:IOVA) raised its full-year 2026 total revenue guidance to between $410 million and $420 million, compared with its previous forecast of $350 million to $370 million. The midpoint of the revised range is $55 million above the midpoint of the previous guidance and represents an increase of approximately 15%.
Iovance shares jump in premarket as raised outlook clears consensus views
Investing.com -- Shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) surged more than 14% in premarket trading Tuesday after the commercial-stage biotechnology company raised its full-year 2026 revenue outlook well above Wall Street expectations. Strong domestic adoption of its flagship tumor-infiltrating lymphocyte therapy, Amtagvi, alongside sustained sales of Proleukin, prompted management to boost its top-line target to between $410 million and $420 million.
Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Iovance Biotherapeutics upgrades 2026 revenue guidance to $410 million-$420 million. Key technicals, analyst targets, and Amtagvi demand analyzed.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's regular session. The market value of their outstanding shares is at $42.5 million. Iovance Biotherapeutics
Crude Oil Down 1%; US Job Openings Fall In August
U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue gui
HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20
HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $9 to $20.
CarMax Posts Upbeat Q2 Earnings, Joins Iovance Biotherapeutics, Perella Weinberg Partners And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed as Dow fell 100+ points; CarMax surged 9.7% on strong results, while Iovance, Carnival and others gained.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%
Why Iovance Biotherapeutics Stock Was on Fire Today
An influential investment bank resumed its coverage of the company.
Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and announces $15 price target.
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
Why Did Iovance Biotherapeutics (IOVA) Move Today?
Iovance Biotherapeutics (IOVA) shares have been active after the company reported record second quarter revenue of nearly US$100 million and a 56% margin, alongside broader plans for its tumor infiltrating lymphocyte platform. Iovance Biotherapeutics has seen momentum build quickly, with a 90-day share price return of 162.15% and a year-to-date share price gain of 306.75%. The 1-year total shareholder return of 400% contrasts with a 5-year total shareholder return that remains down...
Iovance Biotherapeutics (IOVA) Is Up 19.2% After Record Q2 Amtagvi Revenue And TIL Pipeline Expansion
Iovance Biotherapeutics recently reported record second-quarter results, generating nearly US$100 million in revenue with a 56% margin, while rapidly expanding access to its Amtagvi TIL therapy across more authorized treatment centers and broader payer coverage. At the same time, the company is pushing its TIL platform beyond melanoma into lung, sarcoma, and endometrial cancers, and advancing genetically modified TIL and engineered IL-2 programs that could materially reshape its long-term...
Iovance Biotherapeutics (IOVA) Stock Fair Value Edges Higher On Amtagvi Margin Progress
The analyst fair value estimate for Iovance Biotherapeutics has shifted from US$9.33 to US$10.00 per share, reflecting a fresh round of updated models. Recent research points to Amtagvi revenue trends, margin progression, and the potential impact of upcoming data such as IOV-LUN-202 as key reasons behind the new cluster of price targets in the US$10 to US$15 range. Read on to see how these moves fit into the broader analyst narrative and how to track the next set of updates. Analyst Price...
Is Iovance Biotherapeutics (IOVA) Trading At A Premium To Sales?
Iovance Biotherapeutics has seen its stock price move sharply in recent years, which puts fresh attention on whether the current valuation lines up with the scale of its sales. For anyone looking at Iovance today, the key issue is how that share price stacks up against the revenue base supporting it. The stock has returned 400.0% over the past year, which raises a direct question about how much sales performance can underpin that kind of move. The business model, focused on developing and...
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100 million in revenue and a 56% margin. Speaking at the H.C. Wainwright 28th Annu
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 179,750 shares of Iovance’s common stock to eighteen ne
4 Biotech Stocks to Watch as Potential Takeover Targets
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
Why Did CRWD, OKTA, IOVA Shares Climb To 52-Week Highs Today?
CrowdStrike, Okta, and Iovance Biotherapeutics stocks surged to annual highs amid industry tailwinds and positive Wall Street outlooks.
IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside Potential - Here’s Why
Barclays raised Iovance’s price target to $15 from $13 while maintaining an ‘Overweight’ rating, according to The Fly.
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $13 to $15.
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally
The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.
IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights ‘Clear Line Of Sight To Profitability’
Iovance executive Brian Gastman said on Tuesday at a conference that the company’s science was never the hindrance, but getting its therapy to patients.
CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences: Wells Fargo 21st Annual Healthcare ConferenceFireside Chat: September 10, 2026, at 11:00 a.m. ETBoston, MA H.C. Wainwright 28th Annual Global
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-08 | Vogt Frederick G | -15,626 | - | - |
| 2026-09-08 | Vogt Frederick G | -6,638 | $8.7 | $57,751 |
| 2026-09-08 | Vogt Frederick G | +15,626 | - | - |
| 2026-09-08 | BILINSKY IGOR | -7,813 | - | - |
| 2026-09-08 | BILINSKY IGOR | -3,976 | $8.7 | $34,591 |
| 2026-09-08 | BILINSKY IGOR | +7,813 | - | - |
| 2026-09-08 | Puri Raj K. | -9,766 | - | - |
| 2026-09-08 | Puri Raj K. | -4,478 | $8.7 | $38,959 |
| 2026-09-08 | Puri Raj K. | +9,766 | - | - |
| 2026-09-01 | Vogt Frederick G | -41,669 | - | - |
| 2026-09-01 | Vogt Frederick G | -17,702 | $8.28 | $146,573 |
| 2026-09-01 | Vogt Frederick G | +41,669 | - | - |
| 2026-09-01 | Puri Raj K. | -5,470 | - | - |
| 2026-09-01 | Puri Raj K. | -2,508 | $8.28 | $20,766 |
| 2026-09-01 | Puri Raj K. | +5,470 | - | - |
| 2026-09-01 | BILINSKY IGOR | -8,789 | - | - |
| 2026-09-01 | BILINSKY IGOR | -4,472 | $8.28 | $37,028 |
| 2026-09-01 | BILINSKY IGOR | +8,789 | - | - |
| 2026-08-10 | Kirby Daniel Gordon | -10,001 | - | - |
| 2026-08-10 | Kirby Daniel Gordon | -2,436 | $6.4 | $15,590 |
| 2026-08-10 | Kirby Daniel Gordon | +10,001 | - | - |
| 2026-08-06 | Roche Corleen M. | -49,995 | - | - |
| 2026-08-06 | Roche Corleen M. | -21,238 | $6.21 | $131,888 |
| 2026-08-06 | Roche Corleen M. | +49,995 | - | - |
| 2026-06-16 | Dukes Iain D. | +180,632 | - | - |
| 2026-06-16 | Countouriotis Athena | +90,316 | - | - |
| 2026-06-16 | Puri Raj K. | +15,000 | - | - |
| 2026-06-16 | Maynard Ryan D | +90,316 | - | - |
| 2026-06-16 | WEISER MICHAEL | +90,316 | - | - |
| 2026-06-05 | Vogt Frederick G | -15,625 | - | - |
| 2026-06-05 | Vogt Frederick G | -6,638 | $4.23 | $28,079 |
| 2026-06-05 | Vogt Frederick G | +15,625 | - | - |
| 2026-06-05 | GRAF FINCKENSTEIN FRIEDRICH | -7,813 | - | - |
| 2026-06-05 | GRAF FINCKENSTEIN FRIEDRICH | -3,976 | $4.23 | $16,818 |
| 2026-06-05 | GRAF FINCKENSTEIN FRIEDRICH | +7,813 | - | - |
| 2026-06-05 | Puri Raj K. | -9,766 | - | - |
| 2026-06-05 | Puri Raj K. | -3,843 | $4.23 | $16,256 |
| 2026-06-05 | Puri Raj K. | +9,766 | - | - |
| 2026-06-05 | BILINSKY IGOR | -7,813 | - | - |
| 2026-06-05 | BILINSKY IGOR | -3,976 | $4.23 | $16,818 |
| 2026-06-05 | BILINSKY IGOR | +7,813 | - | - |
| 2026-06-01 | Vogt Frederick G | -41,668 | - | - |
| 2026-06-01 | Vogt Frederick G | -17,701 | $3.96 | $70,096 |
| 2026-06-01 | Vogt Frederick G | +41,668 | - | - |
| 2026-06-01 | Puri Raj K. | -5,469 | - | - |
| 2026-06-01 | Puri Raj K. | -2,508 | $3.96 | $9,932 |
| 2026-06-01 | Puri Raj K. | +5,469 | - | - |
| 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH | -8,790 | - | - |
| 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH | -4,473 | $3.96 | $17,713 |
| 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH | +8,790 | - | - |
| 2026-06-01 | BILINSKY IGOR | -8,790 | - | - |
| 2026-06-01 | BILINSKY IGOR | -4,473 | $3.96 | $17,713 |
| 2026-06-01 | BILINSKY IGOR | +8,790 | - | - |
| 2026-05-11 | Kirby Daniel Gordon | -10,000 | - | - |
| 2026-05-11 | Kirby Daniel Gordon | -2,435 | $3.7 | $9,010 |
| 2026-05-11 | Kirby Daniel Gordon | +10,000 | - | - |
| 2026-03-09 | Roche Corleen M. | +132,200 | - | - |
| 2026-03-09 | Vogt Frederick G | +235,000 | - | - |
| 2026-03-09 | Puri Raj K. | +117,500 | - | - |
| 2026-03-09 | GRAF FINCKENSTEIN FRIEDRICH | +58,750 | - | - |
| 2026-03-09 | Kirby Daniel Gordon | +132,200 | - | - |
| 2026-03-09 | BILINSKY IGOR | +117,500 | - | - |
| 2026-03-05 | Vogt Frederick G | -62,493 | - | - |
| 2026-03-05 | Vogt Frederick G | -26,755 | $4.58 | $122,538 |
| 2026-03-05 | Vogt Frederick G | +62,493 | - | - |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH | -31,246 | - | - |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH | -16,520 | $4.58 | $75,662 |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH | +31,246 | - | - |
| 2026-03-05 | Puri Raj K. | -39,059 | - | - |
| 2026-03-05 | Puri Raj K. | -18,360 | $4.58 | $84,089 |
| 2026-03-05 | Puri Raj K. | +39,059 | - | - |
| 2026-03-05 | BILINSKY IGOR | -31,246 | - | - |
| 2026-03-05 | BILINSKY IGOR | -16,628 | $4.58 | $76,156 |
| 2026-03-05 | BILINSKY IGOR | +31,246 | - | - |
| 2026-03-02 | Vogt Frederick G | -10,418 | - | - |
| 2026-03-02 | Vogt Frederick G | -41,669 | - | - |
| 2026-03-02 | Vogt Frederick G | -22,809 | $3.79 | $86,446 |
| 2026-03-02 | Vogt Frederick G | +52,087 | - | - |
| 2026-03-02 | BILINSKY IGOR | -3,517 | - | - |
| 2026-03-02 | BILINSKY IGOR | -8,790 | - | - |
| 2026-03-02 | BILINSKY IGOR | -6,903 | $3.79 | $26,162 |
| 2026-03-02 | BILINSKY IGOR | +12,307 | - | - |
| 2026-03-02 | Puri Raj K. | -5,470 | - | - |
| 2026-03-02 | Puri Raj K. | -2,798 | $3.79 | $10,604 |
| 2026-03-02 | Puri Raj K. | +5,470 | - | - |
| 2026-03-02 | GRAF FINCKENSTEIN FRIEDRICH | -3,907 | - | - |
| 2026-03-02 | GRAF FINCKENSTEIN FRIEDRICH | -8,790 | - | - |
| 2026-03-02 | GRAF FINCKENSTEIN FRIEDRICH | -7,122 | $3.79 | $26,992 |
| 2026-03-02 | GRAF FINCKENSTEIN FRIEDRICH | +12,697 | - | - |
| 2026-02-24 | Kirby Daniel Gordon | -150,000 | - | - |
| 2026-02-24 | Kirby Daniel Gordon | -34,165 | $3.78 | $129,144 |
| 2026-02-24 | Kirby Daniel Gordon | +120,000 | - | - |
| 2026-02-10 | Kirby Daniel Gordon | -39,996 | - | - |
| 2026-02-10 | Kirby Daniel Gordon | -16,450 | $2.6 | $42,770 |
| 2026-02-10 | Kirby Daniel Gordon | +39,996 | - | - |
| 2025-12-02 | GRAF FINCKENSTEIN FRIEDRICH | -3,906 | - | - |
| 2025-12-02 | GRAF FINCKENSTEIN FRIEDRICH | -1,984 | $2.14 | $4,246 |
| 2025-12-02 | GRAF FINCKENSTEIN FRIEDRICH | +3,906 | - | - |
| 2025-12-02 | BILINSKY IGOR | -3,516 | - | - |
| 2025-12-02 | BILINSKY IGOR | -1,786 | $2.14 | $3,822 |
| 2025-12-02 | BILINSKY IGOR | +3,516 | - | - |
| 2025-12-02 | Vogt Frederick G | -10,417 | - | - |
| 2025-12-02 | Vogt Frederick G | -4,426 | $2.14 | $9,472 |
| 2025-12-02 | Vogt Frederick G | +10,417 | - | - |
| 2025-12-01 | GRAF FINCKENSTEIN FRIEDRICH | -8,789 | - | - |
| 2025-12-01 | GRAF FINCKENSTEIN FRIEDRICH | -4,464 | $2.23 | $9,955 |
| 2025-12-01 | GRAF FINCKENSTEIN FRIEDRICH | +8,789 | - | - |
| 2025-12-01 | BILINSKY IGOR | -8,789 | - | - |
| 2025-12-01 | BILINSKY IGOR | -4,464 | $2.23 | $9,955 |
| 2025-12-01 | BILINSKY IGOR | +8,789 | - | - |
| 2025-12-01 | Vogt Frederick G | -41,669 | - | - |
| 2025-12-01 | Vogt Frederick G | -17,701 | $2.23 | $39,473 |
| 2025-12-01 | Vogt Frederick G | +41,669 | - | - |
| 2025-12-01 | Puri Raj K. | -5,469 | - | - |
| 2025-12-01 | Puri Raj K. | -2,467 | $2.23 | $5,501 |
| 2025-12-01 | Puri Raj K. | +5,469 | - | - |